
Molecular Diagnosis of Dysmorphic Syndromes and Inherited Metabolic Disorders in Thailand

VORASUK SHOTELERSUK, MD*

Abstract

While dysmorphic syndromes and inherited metabolic disorders are individually rare, they collectively account for a significant proportion of illnesses, especially in children. They present clinically in a wide variety of ways, involving virtually any organ or tissue of the body making them relatively difficult to diagnose. However, reaching an accurate diagnosis for children with dysmorphic features and suspected inherited metabolic disorders is important to them and their families both for treatment and for the prevention of disease in other family members. It also makes all the accumulated knowledge available about the relevant condition.

Molecular techniques have kindled a revolution in the diagnosis of genetic disorders, including dysmorphic syndromes and inherited metabolic disorders. Molecular methods essentially avoid problems of other techniques. This review exemplifies some of the diseases that can be diagnosed by molecular tools available in Thailand and illustrates some of their benefits.

Key word : Molecular Diagnosis, Dysmorphic Syndromes, Inherited Metabolic Disorders

SHOTELERSUK V

J Med Assoc Thai 2003; 86 (Suppl 2): S129-S134

Dysmorphic syndromes and inherited metabolic disorders are two groups of human diseases that have long been relatively difficult to diagnose and treat, making them bitter pills for many physicians.

Recent advances in molecular techniques in association with the Human Genome Project (HGP) have led to the identification of several human disease genes. One of its benefits would be for diagnosis of these

* Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

diseases. This article exemplifies some of the diseases that can be diagnosed by molecular tools available in Thailand and illustrates some of their benefits.

Molecular diagnosis

Molecular techniques have kindled a revolution in the diagnosis of genetic disorders. In the past, genetic diagnosis was based solely on clinical features, cytogenetic methods, or biochemical tests. Clinical criteria, however, can be indistinct. In addition, some findings may develop later in life, resulting in long periods of ambiguity in the diagnosis. Cytogenetic tests can be used to diagnose only diseases with chromosomal abnormalities, which are not the majority of genetic diseases. Biochemical tests can produce ambiguous results and usually require expensive and invasive studies. Moreover, clinical criteria and biochemical tests have important limitations when used to identify carriers or make a prenatal diagnosis.

Molecular methods essentially avoid these problems. Such methods can unequivocally determine the presence or absence of a gene mutation in a patient or carrier. Because one's genetic material virtually does not change during lifetime, a molecular diagnosis can be made far in advance of the development of clinical symptoms. It requires only a sample of DNA, which is present in any nucleated cells, such as peripheral blood leukocytes. Therefore, there is no need for invasive procedures, for instance a biopsy of affected tissues. Prenatal diagnosis can possibly be made by obtaining chorionic villus or amniotic-fluid cells. Moreover, due to the high specificity of molecular diagnostic testing, screening populations for carriers is possible for some diseases.

Theoretically, molecular diagnosis of any disease whose responsible genes have been identified can be made in Thailand. But practically, due to the heterogeneity and the nature of genetic changes that underlie the disorders, molecular testing for different diseases has different levels of difficulty. Therefore, for disorders that are relatively homogeneous at the molecular level, molecular tests can be performed rapidly (within one day) and inexpensively (could cost in the same range as an echocardiogram or a skeletal survey). But for diseases whose molecular defects are extremely heterogeneous, their molecular testing can be a daunting task. Nonetheless, heterogeneity of molecular defects of majority of diseases lies between these two extremes.

Dysmorphic syndromes

Dysmorphology is the branch of clinical genetics in which clinicians study the patterns of structural defects. Although dysmorphic syndromes are individually rare, collectively they comprise a high proportion of the conditions that affect child health. Reaching an accurate diagnosis for children with dysmorphic features is important to them and their families. It makes available all the accumulated knowledge about the relevant condition.

Molecular techniques allow us to improve our ability to make precise syndrome diagnoses. Unfortunately, responsible genes for many dysmorphic syndromes have not been identified. In fact, several apparently new syndromes have continued to be described. Just early in this year, the authors described an apparent new syndrome in two Thai siblings with postnatal-onset growth deficiency, microcephaly, cataract, prominent supraorbital ridge, large joint contractures, severe osteoporosis, cortical dysplasia, cerebellar atrophy, and mental retardation⁽¹⁾. The description of this new syndrome opens another way of research for the benefits of affected patients and their families.

For syndromes that have long been delineated, more phenotypic features and clinical findings continue to be added. Hydrolethrus syndrome is an autosomal recessive disorder characterized by hydrocephalus, micrognathia, limb anomalies and several other abnormalities, mostly in the midline structures. The syndrome was prevalent in Finland, where all of the Finnish patients were stillborn or died during the first day of life. The authors recently reported a Thai girl with a milder form of hydrolethrus, who survived beyond the neonatal period⁽²⁾.

Diagnoses of dysmorphic syndromes whose molecular defects have not been identified still largely depend on clinical criteria. Kabuki syndrome is a good example. It was first described more than 20 years ago but its true cause remains unknown⁽³⁾.

Thanks to the HGP, scientists have recently identified primary defects for several dysmorphic syndromes. One of the methods to identify the disease gene is to study monozygotic twins who are discordant for the phenotype⁽⁴⁾. After the disease gene is found, mutation analyses and genotype-phenotype correlations can be studied. Cystinosis is an autosomal recessive lysosomal storage disorder characterized by renal Fanconi syndrome and corneal cystine crystal

deposition. There are three types of the disease classified mainly on the age of onset and severity of the disease. After the disease gene was identified⁽⁵⁾, all of the three types were found to be allelic^(6,7) with some correlations between the positions of the genetic changes and the phenotypic features⁽⁸⁻¹⁰⁾. Hermansky-Pudlak syndrome is an autosomal recessive disease with albinism and bleeding diathesis⁽¹¹⁾. Mutations in at least four genes can cause the disease^(12,13). Phenotypic features from each gene are somewhat different⁽¹⁴⁻¹⁶⁾; for example, patients with mutations in *HPS2* gene tend to have neutropenia, which does not usually occur in patients with mutations in other genes⁽¹⁷⁾.

Thai patients with many syndromes have had similar clinical and molecular features to other populations. These include multiple endocrine neoplasia type 2A⁽¹⁸⁾, achondroplasia⁽¹⁹⁾, Crouzon syndrome⁽²⁰⁾, Apert syndrome⁽²⁰⁾ and Pfeiffer syndrome⁽²¹⁾ (Fig. 1). These data can be used in several ways including prenatal diagnosis⁽²²⁾.

Some Thai patients, however, have distinct clinical features even with exactly the same mutations as other patients of different ethnic groups. The authors studied a 15-year-old Thai boy with an unspecified craniosynostosis syndrome who was found to be heterozygous for a 870G->T change in the *FGFR2* gene. This mutation has previously been reported in a Caucasian patient with severe Pfeiffer syndrome type 2 that is distinct from the craniosynostosis in the Thai patient⁽²³⁾.

Several Thai patients have been found to have unique genetic changes. These include Van der Woude syndrome, the most common autosomal dominant cleft syndrome characterized by cleft lip and palate with lip pits⁽²⁴⁾ and pseudoachondroplasia, an autosomal dominant skeletal dysplasia with precocious osteoarthritis⁽²⁵⁾. In addition, the authors found a Thai patient with nasopharyngeal carcinoma (NPC) with a mutation in *FGFR3* gene. It was the first time an *FGFR3*'s role was demonstrated in the development of human NPC⁽²⁶⁾.

Towards the completion of the HGP and the availability of single nucleotide polymorphisms in various ethnic groups, not only genetic defects of single gene disorders can be studied, but also attempts to understand further the genetic components of multifactorial disorders are more feasible and fruitful. The authors recently found that a maternal 677CT/1298AC genotype, a polymorphism in the *MTHFR* gene, is a risk factor for having children with cleft

lips with the odds ratios of 4.43 (95% confidence interval, 1.33-15.10). Approximately 12 per cent of Thai mothers whose children had cleft lips had such genotype. Therefore, folate supplement in a pregnant woman's diet may benefit 12 per cent of Thai children who are susceptible to CL/P due to the 677CT/1298AC genotype in their mothers⁽²⁷⁾.





Fig. 1. The antisense sequence electropherogram (A) showing a heterozygous *FGFR2* S347C (1040C>G) mutation (arrow) helps confirming the diagnosis of Crouzon syndrome in a Thai girl with brachycephaly, exorbitism and maxillary hypoplasia (B).

